Updated:
KBI Biopharma
KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical &...
KBI Biopharma
KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical & Formulation Development, Clinical & Commercial Manufacturing, and more.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Additional offices
Research Triangle Park, NC · Boulder, CO · Louisville, CO · The Woodlands, TX · Geneva, Switzerland · Leuven, Belgium
Principals
JSR Life Sciences
Parent Company
Sector focus
Frequently asked questions
Who runs investment decisions at KBI Biopharma?
KBI Biopharma is not an investment firm; it is a global contract development and manufacturing organization. No publicly available information identifies a chief investment officer or internal investment committee. Capital allocation decisions likely reside with the parent company, JSR Life Sciences, which manages KBI as an operating subsidiary.
How does KBI Biopharma source proprietary deal flow?
As a CDMO, KBI does not pursue proprietary deal flow in the investment sense. Its customer base is built through direct commercial engagement with biopharmaceutical developers who need development and manufacturing services. The company competes for contracts in the outsourced biologics manufacturing market.
Is KBI Biopharma structured as a single family office or does it operate more like a venture firm?
Neither. KBI Biopharma is an operating company and contract development and manufacturing organization within the JSR Life Sciences corporate group. It does not function as a family office, venture capital firm, or investment vehicle. Its business model is service-based, generating revenue from biopharmaceutical clients rather than investing in portfolio companies.
Does KBI Biopharma participate in fund commitments or only direct deals?
KBI Biopharma does not participate in fund commitments or investment deals. It is a CDMO that provides fee-for-service development and manufacturing services to drug developers. There is no public evidence of an affiliated investment arm or corporate venture capital unit.
Which investment stages does KBI Biopharma typically target?
KBI Biopharma does not target investment stages. Its service model spans the drug development lifecycle from cell line development through commercial manufacturing, but this refers to the manufacturing maturity of a client's molecule, not an investment stage. The company supports clients ranging from preclinical startups to commercial-stage biopharmaceutical companies.
Which sectors does KBI Biopharma explicitly avoid?
No public materials identify sectors KBI avoids. The company actively promotes mammalian, microbial, and cell therapy services, suggesting it focuses on biologic modalities. Small-molecule drug manufacturing is not mentioned on the firm's website, indicating the platform may not address that segment.
How is KBI Biopharma related to JSR Life Sciences?
KBI Biopharma is a wholly owned subsidiary of JSR Life Sciences, a global life sciences company headquartered in Japan. JSR Life Sciences provides corporate-level strategic alignment, including sustainability initiatives, while KBI operates its CDMO business across the US and Europe.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: